Antigen Information

General Information of This Antigen (ID: TAR0RKGHS)
Antigen Name
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)
Gene Name
TNFRSF10B
Gene ID
8795
Synonym
DR5; KILLER; TRAILR2; TRICK2; ZTNFR9; Death receptor 5;TNF-related apoptosis-inducing ligand receptor 2;CD262
Sequence
MEQRGQNAPAASGARKRHGPGPREARGARPGPRVPKTLVLVVAAVLLLVSAESALITQQD
LAPQQRAAPQQKRSSPSEGLCPPGHHISEDGRDCISCKYGQDYSTHWNDLLFCLRCTRCD
SGEVELSPCTTTRNTVCQCEEGTFREEDSPEMCRKCRTGCPRGMVKVGDCTPWSDIECVH
KESGTKHSGEVPAVEETVTSSPGTPASPCSLSGIIIGVTVAAVVLIVAVFVCKSLLWKKV
LPYLKGICSGGGGDPERVDRSSQRPGAEDNVLNEIVSILQPTQVPEQEMEVQEPAEPTGV
NMLSPGESEHLLEPAEAERSQRRRLLVPANEGDPTETLRQCFDDFADLVPFDSWEPLMRK
LGLMDNEIKVAKAEAAGHRDTLYTMLIKWVNKTGRDASVHTLLDALETLGERLAKQKIED
HLLSSGKFMYLEGNADSAMS

    Click to Show/Hide
Function
Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.

    Click to Show/Hide
Uniprot Entry
TR10B_HUMAN
HGNC ID
HGNC:11905
KEGG ID
hsa:8795
Each Antibody-drug Conjugate and Its Component Related to This Antigen
Full List of The ADC Related to This Antigen
The Numbers of ADCs, Their Three Components, Payload Targets, and Corresponding Diseases for This Antigens
Anti-DR5 mAb
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Anti-DR5 antibody-curcumin conjugate [1]
Curcumin
Arylamine N-acetyltransferase 2 (NAT2)
Mc-PEG-WDP
 ADC Info 
Zaptuzumab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Oba01 [2]
Monomethyl auristatin E
Microtubule (MT)
PY-MAA-Val-Cit-PABC
 ADC Info 
Zapadcine-1 [3]
Monomethyl auristatin D
Microtubule (MT)
PY-VC-PABC
 ADC Info 
Undisclosed
 Antibody Info 
ADC Name Payload Target Linker ADC Info
RC-248
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
References
Ref 1 An anti-DR5 antibody-curcumin conjugate for the enhanced clearance of activated hepatic stellate cells. Int J Biol Macromol. 2021 Dec 1;192:1231-1239. doi: 10.1016/j.ijbiomac.2021.09.176. Epub 2021 Oct 6.
Ref 2 Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy. Mol Ther Oncolytics. 2021 Apr 29;21:329-339. doi: 10.1016/j.omto.2021.04.013. eCollection 2021 Jun 25.
Ref 3 A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors. Theranostics. 2019 Jul 13;9(18):5412-5423. doi: 10.7150/thno.33598. eCollection 2019.